newsfilter
← Latest News
Earnings Call Transcripts·

Auna 3Q26 Conference Call - AUNA SA

  • Explicit Guidance:

    • Full-year 2026 revenue growth expected within 10%–14% (FX-neutral basis).
    • Full-year 2026 adjusted EBITDA expected to remain broadly stable or slightly down year-over-year, driven by Colombia's oncology contract termination costs and regulatory price caps.
    • Full-year 2026 capital expenditures (capex) guidance maintained at approximately 4% of consolidated revenues.
    • Medium-term leverage ratio target set at 3.0 times.
    • Peru EBITDA margins expected to recover toward historical levels in the low 20s.
    • Peru billing reconciliations expected to normalize by the second half of 2027.
    • Colombia price caps on high-cost oncology medicines expected to impact Q4 2026 results significantly (impacted 30% in Q3 due to mid-quarter implementation; full 3-month impact expected in Q4).
    • FX hedge reset: Future FX variances expected to be minimal, occurring only if USD/SOL moves outside the 3.4–3.8 range.
  • Business-Segment Outlook:

    • Mexico: Positioned for sustained growth and improving profitability; 2027 target is adding 2–3 percentage points to capacity utilization annually. Monterrey network EBITDA margin at 28% with 41% occupancy. Expect continued EBITDA growth in Q4 driven by volume recovery and operating leverage. Out-of-pocket payments (currently ~9% of revenue) expected to double.
    • Peru: Focus on expanding high-complexity services beyond oncology (neurosurgery, traumatology, orthopedics, cardiovascular surgery). B2B account onboarding expected to normalize profitability by Q4 2026 following the addition of ~4,000 PAN members. Asset-light strategy emphasized to manage capacity; comfortable operating at 90% utilization before triggering expansion.
    • Colombia: Expect gradual recovery to become a profitable growth contributor, supported by ICU/hospitalization expansion in Montería and PGP arrangements. Near-term headwinds include regulatory price caps and structural cost pressures; profitability expected to improve as new contract economics take hold.
    • OncoSalud (Peru): No specific structural headwinds identified; growth strategy focuses on product diversification (different price points, coverage levels) to address limited disposable income while maintaining affordability and early detection focus.
  • Market and Competitive Outlook:

    • Mexico Insurance Market: Industry-wide headwinds from VAT deductibility regulations expected to continue shrinking market volume (approx. 1 million policies lost), but AUNA expected to gain market share due to attractive pricing and cost containment capabilities.
    • Competitive Landscape: Mexico's VAT changes create a benefit for operators with the most attractive cost points, reinforcing AUNA's growth trajectory despite sector contraction.
    • Out-of-Pocket Market: Significant opportunity in Mexico to double the current ~9% out-of-pocket revenue mix given high household health expenditure burden.
  • Macro / Industry Outlook:

    • Regulatory Environment: Colombia's regulatory price caps on high-cost oncology medicines enacted mid-August will persist into Q4 and beyond; management actively managing revenue mix to mitigate impact.
    • El Niño Phenomenon: Strong to extremely strong El Niño forecast for late 2026/early 2027; management has activated operational continuity plans including infrastructure reinforcement, critical medicine supply stockpiling, fuel/water/electricity backups, and patient flow coordination across Northern Peru, Arequipa, and Lima.
    • Wage Pressures: Colombia faces ongoing inflationary pressure from mandatory wage increases and statutory work hour reductions.
  • Strategic Initiatives:

    • Centro Ambulatorio Torre Treca (Peru): Construction on schedule with first payments disbursed; project expected to demonstrate B2G capabilities. Anticipated to serve as a template for future B2G and PPP projects (valued at 5–6x private sector multiples).
    • M&A/Partnerships: Progress on SOGIES MOU; expected announcement of partnership by early 2027.
    • Capacity Expansion: Continued expansion of ICU and hospitalization capacity in Montería, IMAT, and OncoMedica (Colombia).
    • Product Expansion: Development of oncology insurance franchise in Mexico to deepen vertical integration.
    • Risk Management: Termination of specific high-cost oncology risk-sharing contract in Colombia (approx. 4% of revenue) to eliminate exposure; legal counsel engaged for recovery options.
    • Debt Management: Reviewing refinancing opportunities for remaining $100M of 2029 bonds (callable at 105% at end of 2026).
  • Risks and Headwinds to Outlook:

    • Colombia: Extraordinary medical costs from terminated oncology contract; regulatory price caps on oncology medicines; high personnel costs and structural operating costs.
    • Peru: Revenue reconciliation impacts from prior years (estimated $18M soles impact in Q3); continued revenue adjustments expected through Q4.
    • Macro: Volatility in FX (though hedged) and the potential impact of El Niño on operations and supply chains.
    • Contract Specifics: Specific risk-sharing contracts may carry high incidence risk not reflective of the broader portfolio (confirmed as non-contagious to other PGPs/PIPs).
  • Management Tone on the Future:

    • Confidence remains high in the long-term potential of the integrated regional platform and Mexico/Peru growth stories.
    • Acknowledgment of "dirty quarters" (2026) due to exogenous events; emphasis on shifting focus to predictability and control over operational results.
    • Commitment to restoring profitability in Colombia and improving earnings quality in Peru while accelerating growth in Mexico.
    • Strong cash generation and deleveraging progress viewed as enabling further strategic investments.
  • Miscellaneous:

    • No explicit quarterly revenue/earnings guidance provided beyond full-year 2026; full-year revenue growth of 10%–14% and stable/down EBITDA are the primary forward metrics.
    • Blended interest rate currently at 10.38% YTD (including hedges and local currency funding).
    • 54% of gross debt in local currencies; 85% of USD debt hedged against SOL; 75% of floating Mexican debt hedged.
    • 90% of payer relationships in Mexico have confirmed current operating tiers.
    • OncoSalud's MLR stood at 50.7% in Q3.
    • Free cash flow surge of 95% YTD to 626 million soles.
Company
AUNA SA
Keywords
AUNA SA